Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Ha San Lin's wholly-owned subsidiary expands business scope, adding the production and sales of food additives and pharmaceutical excipients.
March 24, Harbin Sanlian Pharmaceutical Co., Ltd. (Securities Code: 002900, Securities Short Name: Harsanlian) released an announcement stating that its wholly owned subsidiary, Lanxi Harbin Sanlian Pharmaceutical Co., Ltd. (hereinafter referred to as “Lanxi Harbin Sanlian”), has completed the business scope change and the industrial and commercial registration procedures, and obtained a renewed business license issued by the Lanxi County Market Supervision and Administration Bureau. This adjustment to the business scope indicates that Lanxi Harbin Sanlian’s business layout in the pharmaceutical industry chain and related fields has been further expanded.
According to the announcement, based on its existing business, Lanxi Harbin Sanlian has added multiple licensed projects and general projects. For licensed projects, it added “food additive production,” “production of pharmaceutical excipients,” “sales of pharmaceutical excipients,” and “import and export of pharmaceuticals.” For general projects, it added “sales of food additives” and “import and export of food.”
Harbin Sanlian stated that the change in the subsidiary’s business scope is intended to better adapt to market development needs, expand business areas, and enhance the company’s overall competitiveness. Other registration matters on Lanxi Harbin Sanlian’s business license, besides the above business scope change, remain unchanged.
This business expansion will enable Lanxi Harbin Sanlian to extend from a traditional pharmaceutical manufacturing enterprise to upstream and downstream segments of the pharmaceutical industry chain. Particularly in the areas of pharmaceutical excipients and food additives, the company is expected to bring new profit growth opportunities, while also improving its comprehensive service capabilities in the pharmaceutical and health sector. Market analysts believe that demand for pharmaceutical excipients and food additives is stable, and Harbin Sanlian’s move will help optimize its product structure and diversify operating risks.
Harbin Sanlian emphasized that the launch of the relevant newly added businesses still requires approvals or licenses from relevant authorities. The company will, in accordance with the requirements of laws and regulations, actively handle the related procedures to ensure that all businesses operate legally and in compliance.
Click to view the full text of the announcement>>
Disclaimer: The market involves risk; investment should be approached with caution. This article is automatically published by an AI large model based on third-party databases, and does not represent Sina Finance’s viewpoint. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there are any discrepancies, please refer to the actual announcement. If you have any questions, please contact biz@staff.sina.com.cn.
A vast amount of information and precise analysis—right on the Sina Finance app
Responsible editor: Xiao Lang Express